Profound Medical to join Lake Street BIG10 investor event

Profound Medical Corp. (PROF) reported that its management will participate in the Lake Street Capital Markets “BIG10” Conference on September 10, 2026, in New York City, as disclosed under a Regulation FD communication.

Rhea-AI Filing Summary

Profound Medical Corp. (PROF) reported that its management will participate in the Lake Street Capital Markets “BIG10” Conference on September 10, 2026, in New York City, as disclosed under a Regulation FD communication. The event will consist of one-on-one investor meetings and will not include a webcast.

The accompanying press release also reiterates that Profound is a commercial-stage medical device company focused on MRI-guided, incision-free therapies through its TULSA-PRO and Sonalleve platforms, which are cleared or approved in multiple major global markets for various prostate, oncologic, and gynecologic indications.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Conference date: September 10, 2026 Press release date: September 3, 2026 Trading symbol: PROF +2 more

5 metrics

Conference date September 10, 2026 Date of Lake Street Capital Markets “BIG10” Conference where management will participate

Press release date September 3, 2026 Date of the Profound Medical press release furnished as Exhibit 99.1

Trading symbol PROF Ticker for Profound Medical Corp. common shares on The Nasdaq Stock Market

Principal office telephone 647-476-1350 Registrant’s telephone number at its principal executive offices in Mississauga, Ontario

Investor relations telephone 647-872-4849 Telephone number provided for investor relations contact Stephen Kilmer

Key Terms

Regulation FD, interventional MRI (iMRI), TULSA-PRO, transurethral ultrasound ablation (TULSA), +1 more

5 terms

Regulation FD regulatory

"Item 7.01. Regulation FD Disclosure."

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

interventional MRI (iMRI) medical

"an innovator in interventional MRI (iMRI) procedures"

TULSA-PRO medical

"The company’s flagship platform, TULSA-PRO®, enables MRI-guided"

transurethral ultrasound ablation (TULSA) medical

"cleared by the FDA in the United States for transurethral ultrasound ablation (TULSA) of prostate tissue"

Humanitarian Device Exemption (HDE) regulatory

"Sonalleve is approved by the FDA as HDE in the United States"

FAQ

What did Profound Medical Corp. (PROF) announce in this 8-K?

Profound Medical Corp. announced that management will participate in the Lake Street Capital Markets “BIG10” Conference on September 10, 2026, in New York City, holding one-on-one investor meetings. The company also furnished a press release as Exhibit 99.1 describing the event participation.

Will Profound Medical (PROF) provide a webcast for the Lake Street BIG10 Conference?

No. Profound Medical stated that, due to the format of the Lake Street Capital Markets “BIG10” Conference, the event will consist of one-on-one investor meetings and that no webcast will be available.

When was the Profound Medical (PROF) press release about the conference issued?

The press release announcing Profound Medical’s participation in the Lake Street Capital Markets “BIG10” Conference was dated September 3, 2026. This release is furnished as Exhibit 99.1 to the current report.

Under which item and regulation did Profound Medical (PROF) report this information?

Profound Medical reported this information under Item 7.01, Regulation FD Disclosure. The company specified that the information, including Exhibit 99.1, is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act.

What are Profound Medical’s main commercial platforms mentioned in the filing?

Profound Medical highlights two main platforms: TULSA-PRO, which enables MRI-guided, incision-free prostate tissue ablation, and Sonalleve, an MRI-guided therapy for pain palliation of bone metastases, desmoid tumors, osteoid osteoma, and gynecologic conditions such as uterine fibroids and adenomyosis.

On which exchange are Profound Medical (PROF) shares listed?

Profound Medical’s common shares, with no par value per share, trade under the symbol PROF on The Nasdaq Stock Market, as stated in the securities registration section.

Who signed the Profound Medical (PROF) 8-K related to the Lake Street conference?

The report was signed on behalf of Profound Medical Corp. by Arun Menawat, who is identified as the company’s Chief Executive Officer and Chairman, dated September 3, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 06:03 AM Accepted by SEC EDGAR 09/03/2026 - 09:00 PM Learn about SEC filing dates

False000162880800016288082026-09-032026-09-03iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  September 3, 2026

_______________________________

PROFOUND MEDICAL CORP.

(Exact name of registrant as specified in its charter)

_______________________________

Ontario, Canada	001-39032	Not Applicable
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

2400 Skymark Avenue, Unit 6

Mississauga, Ontario, Canada L4W 5K5

(Address of Principal Executive Offices) (Zip Code)

Registrant's Telephone Number, Including Area Code: 647-476-1350

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares, No Par Value Per Share	PROF	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On September 3, 2026, Profound Medical Corp. (the “Company” or “Profound”) issued a press release announcing that the Company’s management will participate in the Lake Street Capital Markets “BIG10” Conference on September 10, 2026 in New York City. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. 

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated September 3, 2026
104		Cover Page Interactive Data File (embedded within Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PROFOUND MEDICAL CORP.
Date: September 3, 2026	By:	/s/ Arun Menawat
		Arun Menawat
		Chief Executive Officer and Chairman

EXHIBIT 99.1

Profound Medical to Participate in Lake Street’s 10th Annual Best Ideas Growth Conference

TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, announced today that management will participate in the Lake Street Capital Markets “BIG10” Conference on September 10, 2026 in New York City.

The event will consist of one-on-one investor meetings. Due to the format of the event, no webcast will be available.

About Profound Medical Corp.

Profound is a commercial-stage medical device company and an innovator in interventional MRI (iMRI) procedures. The company’s flagship platform, TULSA-PRO^®, enables MRI-guided, incision-free prostate ablation. Physicians use the TULSA Procedure™ to see, ablate, and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care—from whole-gland to subtotal, hemi, multifocal, and focal treatment. This approach enables individualized care using prostate tissue ablation, while minimizing the potential of the side effects that are typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.

Profound also commercializes Sonalleve^®, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumors, and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis. Sonalleve delivers targeted therapy with no incisions, no blood loss during the procedure, no overnight hospital stay, and faster recovery — and, in gynecologic applications, enables uterine-sparing treatment that may help preserve fertility. Profound is also exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.

Profound Medical’s technologies are approved across major global markets. TULSA-PRO is cleared by the FDA in the United States for transurethral ultrasound ablation (TULSA) of prostate tissue. In addition, TULSA-PRO is cleared for use in various jurisdictions including Europe, Canada, Saudi Arabia, India, Australia/New Zealand, and the UAE. Sonalleve is approved by the FDA as HDE in the United States for the treatment of osteoid osteomas in the extremities. Sonalleve is also cleared or approved in the Europe, Canada, China, and Saudi Arabia.

Through real-time MRI guidance and data-driven innovation, Profound is advancing the future of MRI-guided therapy — expanding access to precise, personalized, and incision-free treatment options worldwide.

For further information, please contact:

Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com  
T: 647.872.4849

Filing Exhibits & Attachments

5 documents

Press Releases

• EX-99.1 PRESS RELEASE 3.8 KB

Other Documents

• EX-101 XBRL SCHEMA FILE 3.3 KB
• EX-101 XBRL DEFINITION FILE 25.5 KB
• EX-101 XBRL LABEL FILE 35.1 KB
• EX-101 XBRL PRESENTATION FILE 24.1 KB